Saxagliptin
id:
saxagliptin-292-6933743
title:
Saxagliptin
text:
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In April 2016, the U.S. FDA added a warning about increased risk of heart failure. This was based on data in an article that concluded "DPP-4 inhibition with saxagliptin did not increase
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Saxagliptin
date created:
date modified:
2024-04-05T20:50:52Z
main entity:
{"identifier":"Q3121121","url":"https://www.wikidata.org/entity/Q3121121"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/e/ed/Saxagliptin_structure.svg","width":512,"height":325}
fields total:
13
integrity:
15